Rituximab Therapy in Autoimmune Pulmonary Alveolar Proteinosis

Overview

Journal Eur Respir J

Specialty Pulmonary Medicine

Date 2009 Jun 2

PMID 19483052

Citations 38

Authors

R Borie

M-P Debray

C Laine

M Aubier

B Crestani

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary alveolar proteinosis is presumed to be an autoimmune disorder that may lead to pulmonary insufficiency. However, steroids do not appear to be effective and the standard of therapy is whole-lung lavage. We report the first case of successful therapy with rituximab, which addresses the pathogenic mechanism of pulmonary alveolar proteinosis.

Citing Articles

Rituximab Therapy in Pulmonary Alveolar Proteinosis: A Case Report.

Fikri O, Hindi M, Amro L Cureus. 2024; 16(11):e73836.

PMID: 39691114 PMC: 11650403. DOI: 10.7759/cureus.73836.

Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis.

Kulkarni T, Criner G, Kass D, Rosas I, Scholand M, Dilling D BMC Pulm Med. 2024; 24(1):143.

PMID: 38509495 PMC: 10953157. DOI: 10.1186/s12890-024-02957-3.

Design of the STRIVE-IPF Trial- Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.

Kulkarni T, Criner G, Kass D, Rosas I, Scholand M, Dilling D Res Sq. 2024; .

PMID: 38464052 PMC: 10925430. DOI: 10.21203/rs.3.rs-3962419/v1.

Nebulised granulocyte-macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis.

Munsif M, Sweeney D, Leong T, Stirling R Eur Respir Rev. 2023; 32(170).

PMID: 37993127 PMC: 10663936. DOI: 10.1183/16000617.0080-2023.

Alveolar macrophages in pulmonary alveolar proteinosis: origin, function, and therapeutic strategies.

Huang X, Cao M, Xiao Y Front Immunol. 2023; 14:1195988.

PMID: 37388737 PMC: 10303123. DOI: 10.3389/fimmu.2023.1195988.